---
title: "INSMED Chair and CEO William Lewis Sells 13,396 Shares"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275664348.md"
description: "INSMED's Chair and CEO, William Lewis, sold 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan, totaling $1,979,763. The shares were sold at average prices of $147.17, $148.02, and $148.83. Post-sale, Lewis holds 301,185 shares directly and 284,424 shares indirectly through trusts."
datetime: "2026-02-11T21:50:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275664348.md)
  - [en](https://longbridge.com/en/news/275664348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275664348.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275664348.md) | [繁體中文](https://longbridge.com/zh-HK/news/275664348.md)


# INSMED Chair and CEO William Lewis Sells 13,396 Shares

INSMED's Chair and CEO, William Lewis, sold a total of 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan. The transactions occurred at weighted average prices of $147.17, $148.02, and $148.83, resulting in a total sale amount of $1,979,763. Following these transactions, Lewis directly owns 301,185 shares and indirectly owns 284,424 shares of INSMED common stock through the Katie Procter Dynasty Trust and the William Lewis Family Legacy Trust.

Reporter Name

Lewis William

Relationship

Chair and CEO

Type

Sell

Amount

$1,979,763

SEC Filing

Form 4

SEC Filing: INSMED Inc \[ INSM \] - Form 4 - Feb. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相关股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Insmed (INSM.US)](https://longbridge.com/zh-CN/quote/INSM.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [Invesco Dorsey Wright Healthcare Momentum ETF (PTH.US)](https://longbridge.com/zh-CN/quote/PTH.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)

## 相关资讯与研究

- [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/zh-CN/news/279503772.md)
- [Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data](https://longbridge.com/zh-CN/news/279614662.md)
- [Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results](https://longbridge.com/zh-CN/news/279269040.md)
- [Cybin Inc. Publishes Corporate Presentation on HLP003 and HLP004 Serotonergic Agonist Programs for MDD and GAD](https://longbridge.com/zh-CN/news/279625297.md)
- [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/zh-CN/news/279429425.md)